Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: FAM229B

Gene summary for FAM229B

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

FAM229B

Gene ID

619208

Gene namefamily with sequence similarity 229 member B
Gene AliasC6orf225
Cytomap6q21
Gene Typeprotein-coding
GO ID

GO:0003674

UniProtAcc

Q4G0N7


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
619208FAM229BLZE24THumanEsophagusESCC4.60e-064.29e-010.0596
619208FAM229BP2T-EHumanEsophagusESCC3.09e-224.42e-010.1177
619208FAM229BP4T-EHumanEsophagusESCC2.97e-113.09e-010.1323
619208FAM229BP8T-EHumanEsophagusESCC4.37e-162.58e-010.0889
619208FAM229BP10T-EHumanEsophagusESCC1.19e-112.64e-010.116
619208FAM229BP11T-EHumanEsophagusESCC1.10e-083.08e-010.1426
619208FAM229BP12T-EHumanEsophagusESCC1.36e-041.35e-010.1122
619208FAM229BP16T-EHumanEsophagusESCC4.27e-213.85e-010.1153
619208FAM229BP17T-EHumanEsophagusESCC2.80e-022.60e-010.1278
619208FAM229BP19T-EHumanEsophagusESCC1.02e-074.36e-010.1662
619208FAM229BP21T-EHumanEsophagusESCC1.87e-121.83e-010.1617
619208FAM229BP22T-EHumanEsophagusESCC9.27e-141.83e-010.1236
619208FAM229BP23T-EHumanEsophagusESCC4.56e-061.59e-010.108
619208FAM229BP24T-EHumanEsophagusESCC2.93e-091.37e-010.1287
619208FAM229BP26T-EHumanEsophagusESCC1.60e-203.40e-010.1276
619208FAM229BP27T-EHumanEsophagusESCC5.58e-132.70e-010.1055
619208FAM229BP32T-EHumanEsophagusESCC1.55e-132.90e-010.1666
619208FAM229BP37T-EHumanEsophagusESCC2.35e-092.48e-010.1371
619208FAM229BP44T-EHumanEsophagusESCC8.63e-052.88e-010.1096
619208FAM229BP47T-EHumanEsophagusESCC2.45e-067.61e-020.1067
Page: 1 2 3 4 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
Page: 1 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
FAM229BSNVMissense_Mutationc.64G>Ap.Glu22Lysp.E22KQ4G0N7protein_codingtolerated_low_confidence(0.12)benign(0.021)TCGA-3C-AALI-01Breastbreast invasive carcinomaFemale<65I/IIUnspecificPoly EComplete Response
FAM229BdeletionFrame_Shift_Delnovelc.91delNp.Ala31LeufsTer23p.A31Lfs*23Q4G0N7protein_codingTCGA-D8-A27V-01Breastbreast invasive carcinomaFemale<65I/IIHormone TherapytamoxiphenSD
FAM229BSNVMissense_Mutationrs149743977c.197C>Tp.Thr66Metp.T66MQ4G0N7protein_codingtolerated_low_confidence(1)benign(0)TCGA-AA-3950-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
FAM229BSNVMissense_Mutationc.64N>Ap.Glu22Lysp.E22KQ4G0N7protein_codingtolerated_low_confidence(0.12)benign(0.021)TCGA-AD-6899-01Colorectumcolon adenocarcinomaMale>=65III/IVUnknownUnknownSD
FAM229BSNVMissense_Mutationnovelc.52N>Tp.Asp18Tyrp.D18YQ4G0N7protein_codingdeleterious_low_confidence(0)probably_damaging(0.998)TCGA-AJ-A5DW-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
FAM229BSNVMissense_Mutationnovelc.19N>Cp.Thr7Prop.T7PQ4G0N7protein_codingtolerated_low_confidence(0.18)possibly_damaging(0.529)TCGA-D1-A0ZP-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapypaclitaxelPD
FAM229BSNVMissense_Mutationnovelc.62N>Cp.Ile21Thrp.I21TQ4G0N7protein_codingtolerated_low_confidence(0.08)benign(0)TCGA-EO-A3AZ-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
FAM229BdeletionFrame_Shift_Delnovelc.145delNp.Gly49GlufsTer5p.G49Efs*5Q4G0N7protein_codingTCGA-97-8179-01Lunglung adenocarcinomaMale>=65I/IIUnknownUnknownSD
FAM229BdeletionFrame_Shift_Delc.75delTp.Leu27Terp.L27*Q4G0N7protein_codingTCGA-NJ-A4YP-01Lunglung adenocarcinomaMale<65I/IIUnknownUnknownSD
FAM229BSNVMissense_Mutationrs782240107c.175N>Tp.Pro59Serp.P59SQ4G0N7protein_codingtolerated_low_confidence(0.07)probably_damaging(0.998)TCGA-CV-7568-01Oral cavityhead & neck squamous cell carcinomaFemale<65I/IIUnknownUnknownSD
Page: 1 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1